Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

North Bud Farms $NBUD.ca Announces Proposed Terms for the Second Tranche of its Non-Brokered Private Placement and Provides a Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:11 PM on Monday, January 27th, 2020
  • First tranche of the Offering closed on November 6, 2019, at which time the Company issued an aggregate of 1,264 Units for gross proceeds of $1,264,000
  • Accordingly, the Company can issue up to an additional $2,736,000 of Units under the Second Tranche
  • In the context of a regular follow-up communication with Health Canada, representatives of the Company received verbal feedback that the application review is complete and the reviewers do not have any more questions.

TORONTO, Jan. 27, 2020 – North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce that it is arranging a closing for the second tranche (the “Second Tranche“) of its non-brokered private placement of 10% secured convertible debenture units (the “Units“) of the Company at a price of C$1,000 for gross proceeds of up to C$4,000,000, originally announced on November 6, 2019 (the “Offering“). The first tranche of the Offering closed on November 6, 2019, at which time the Company issued an aggregate of 1,264 Units for gross proceeds of $1,264,000. Accordingly, the Company can issue up to an additional $2,736,000 of Units under the Second Tranche.

Each Unit issued in connection with the Second Tranche of the Offering is comprised of one C$1,000 principal amount of secured convertible debenture (a “Convertible Debenture“) accruing interest at 10.0% per annum, payable semi-annually in arrears until maturity, and 5,556 common share purchase warrants of the Company (each, a “Warrant“). The Convertible Debentures will have a maturity date of 36 months from the date of issuance. In addition, under the Second Tranche, the Company has the right to prepay an amount equal to the 1st year of interest to be earned by issuing common shares at a deemed price of $0.25 per common share (the “Prepaid Interest Shares”) on the 15th day following the Closing Date should the holders of the Convertible Debentures not elect to receive their 1st year interest paid in cash.

Each Convertible Debenture shall be convertible into common shares in the capital of the Company (each, a “Conversion Share“) at a price of $0.18 (the “Conversion Price“) per Conversion Share.

Each Warrant entitles the holder thereof to acquire one common share in the capital of the Company (each, a “Warrant Share“) for an exercise price of $0.30 per Warrant Share for a period of 36 months following the closing date.

The Convertible Debentures are direct secured obligations of the Company and rank pari passu in right of payment of principal and interest with all other Convertible Debentures issued under the Offering.

Certain directors of the Company have indicated that they may participate in the private placement. Any such purchase would constitute a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The proposed issuance to directors of the Company would be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of any Units issued to or the consideration paid by such insiders would not exceed 25% of the Company’s market capitalization.

The Company may pay registered dealers (the “Finders“) a cash commission equal to up to 8% of the aggregate gross proceeds from the sale of the Units sold pursuant to the Offering to eligible investors introduced to the Company by such Finders. In addition, the Company will grant warrants (the “Compensation Warrants”) exercisable at the Conversion Price for a period of 24 months from the Closing Date to acquire in aggregate the number of Common Shares equal to 8% of the gross proceeds under the Offering divided by the Conversion Price.

The proceeds of the Second Tranche will be used by the Company for expansion of the Company’s facilities and for general corporate and working capital purposes.

The Convertible Debentures, Warrants, Prepaid Interest Shares (if any), and any Compensation Warrants issued pursuant to the Second Tranche of the Offering and any common shares in the capital of the Company issued on conversion of the Convertible Debentures or exercise of the Warrants or Compensation Warrants will be subject to a statutory hold period in Canada of four months and one day following the closing date in accordance with applicable securities laws. Additional resale restrictions may be applicable under the laws of other jurisdictions, if any.

The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Amendment to Securities Issued in First Tranche of the Offering

The Company further announces that, in order to ensure equitable treatment of holders, it has decided to amend the terms of the debentures (the “First Tranche Debentures“) and warrants (the “First Tranche Warrants“) issued under the first tranche of the Offering, which closed on November 6, 2019. The Company has amended the First Tranche Debentures to reduce the conversion price to $0.18 per common share and has amended the terms of the First Tranche Warrants to: (a) increase the number of warrants issued per $1000 of principal amount of debenture from 2,000 to 5,556; (b) increase the exercise price from $0.25 to $0.30 per warrant; and (c) extend the expiry date of the warrants from 18 months following the closing date to 36 months following the closing date. The amendments are subject to the final approval of the Canadian Securities Exchange (CSE).

Corporate Update

The Company would also like to provide an update regarding the status of its standard cultivation licence application with Health Canada under the Cannabis Act. In the context of a regular follow-up communication with Health Canada, representatives of the Company received verbal feedback that the application review is complete and the reviewers do not have any more questions. Subject to the re-submission of a required foreign police certificate related to one of the foreign directors of the Company, the Company will be in the final queue for receiving its licence. The Company is confident that it will be able to file the certificate promptly; however, there can be no assurance as to the exact timing of the issuance of the licence by Health Canada or whether the Company will receive any final request from Health Canada.

Further to the Company’s announcement regarding its acquisition of certain California-based businesses on November 22, 2019, the Company has proceeded with the issuance of 1,716,000 common shares, at an issue price of $0.25 per share, to an arm’s length advisor to the Company. The shares, which are subject to a statutory hold period as required by applicable securities laws, are based upon the $429,000 cash value of the 3% M&A fee payable to such advisor in respect of the foregoing California acquisitions.

About North Bud Farms Inc.
North Bud Farms Inc., through its U.S. subsidiary Bonfire Brands USA, has acquired cannabis production facilities in California and in Nevada. The Salinas, California 11-acre farm is actively cultivating cannabis in its 60,000 sq. ft. of licensed greenhouse production space. The Reno, Nevada property is located on 3.2-acres of land which was acquired through the acquisition of Nevada Botanical Science, Inc. a world class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation which holds medical and adult use licenses for cultivation, extraction and distribution. Through its wholly owned Canadian subsidiary, GrowPros MMP Inc., the company is pursuing a licence under The Cannabis Act, to cultivate in its state-of-the-art purpose-built cannabis production facility located on 135-acres of Agricultural Land in Low, Quebec, Canada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE“) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, statements related to the intended use of proceeds from the Offering, and the status of the Company’s licence application with Health Canada under the Cannabis Act. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com. 

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , , , , ,
Posted in All Recent Posts, Featured, North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Announces Proposed Terms for the Second Tranche of its Non-Brokered Private Placement and Provides a Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

NORTHBUD $NBUD.ca – Cannabis Industry: 2020 Predictions $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 5:24 PM on Monday, January 27th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Cannabis Industry: 2020 Predictions

  • Cannabis Legalization Is Going Global
  • Real Medical Testing Will Increase
  • Older Customers Will Expand Their Cannabis Purchases Beyond Medical Use

By: Julie Weed Contributor

Here, industry executives predict top trends for 2020.

Cannabis Legalization Is Going Global

Legalization is growing outside of the United States, and countries that are first to the global marketplace can create sustainable advantages for themselves in their customer base and their funding. Kyle Detwiler, chief executive of Clever Leaves, an international operator with brands, extraction facilities, cultivation operations, and other investments in six countries, says that countries like Colombia and Portugal that have been among the first to legalize cannabis “are poised to continue establishing their global dominance in short order.”

The countries’ first-mover status will also be a magnet for financial interest he said. “There is little doubt that the expanding European cannabis market will make it an attractive investment opportunity,” Detwiler said.

Hemp, the source for CBD in many non-psychoactive products, will expand internationally as well, driven by the CBD’s demand. The CBD market will grow to $2.1 billion in consumer sales by 2020 according to the Hemp Business Journal, with $450 million of those sales coming from hemp-based sources. Puerto Rico’s Department of Agriculture has already reported there will be at least 10,000 acres of hemp cultivated for commercial purposes in 2020

The CBD Product Market Will Mature

CBD is being added to products across the retail spectrum from food to make-up, but with little legal oversight or requirements, the products can easily be mislabeled or ineffective. Clever Leaves chief executive Detwiler says in 2020 CBD standards will begin to emerge based on customer demand. “Consumers are getting more savvy on the benefits of CBD and they will begin to insist on knowing exactly what they are paying for and what they are getting when they purchase ‘CBD’,” Detwiller said.

Consumers will “begin to insist” on CBD standards agrees Bill Thurman, chief executive of Redbird Bioscience a medical cannabis operator and producer of pharmaceutical-grade cannabis for patients in Oklahoma.

Thurman said companies will help the market succeed as a whole if they adhere to high quality standards and agreed-upon guidelines in testing and manufacturing. That kind of rigor is needed to significantly increase the size of the market and only by conducting “science-driven randomized clinical studies, can we shed reliance on anecdotal data to support medical claims,” he said. 

Barbara Goodstein of B GREAT  which produces full-spectrum upscale CBD items expects CBD to be added to even more products like deodorant, hand soaps, throat sprays and nasal sprays. The popularity of the category also creates additional business risks according to Goodstein. “The hype around this space will end up creating applications and uses that make no sense, which will unfortunately diminish the real value of the product,” she said.

Real Medical Testing Will Increase

Until cannabis is taken of the Schedule One substance list, medical research will be challenging to undertake. Still, executives in the industry are seeing some movement in the area. Israel still leads the world in global cannabis research, and Israeli scientists like chemist Raphael Mechoulam, a researcher at Hebrew University and pioneer in cannabis research, are being hired or given research grants by American organizations.

Dr. William Levine, founder and chief scientific officer of CannRx a subsidiary of Izun Pharmaceuticals that develops proprietary medical and recreational products expects companies to use better data, and well-designed clinical trials. His own company is focused on better “bio-availability” which focuses on lower dose products that can offer similar benefits to higher dose products, but with fewer side effects.

Older Customers Will Expand Their Cannabis Purchases Beyond Medical Use

CannRx’s Levine predicts there will be “increased recreational expansion into older populations,” as product quality and more controlled dosing options come to market.

Legislative Action Will Remain Robust

According to Marijuana Moment, as of January 16, there were 975 cannabis-related bills moving through state legislatures and Congress for 2020 sessions.

“We expect to see a lot more regulatory activity in 2020 on both the state and federal levels,” said Redbird Bioscience’s Thurman.

Each state makes its own rules. For example, regarding medical marijuana use, some states have a list of specific ailments that can warrant a recommendation of the substance (states include Florida and New Jersey). In other states the decision to use medical marijuana is entirely between patient and doctor (states include Oklahoma and California.)

States will have more models to look to as they develop their laws and will likely start adopting each others’ best practices. Law makers will start learning more from each other’s experiences and “harmonize” their regulations with each other said Levine. He also believes the federal government could take the first step to legalize medical marijuana.

Matt Anderson, chief executive of Vanguard Scientific, a company that provides service resources for cannabis and hemp botanical extraction, says just the ongoing discussion of legalization and decriminalization will continue to drive market growth.

Multi-state Operators Will Face A Shake-out

Running a cannabis business is expensive, and running a multi-state cannabis business when each state has its own rules to abide by make it hard to achieve economies of scale. Lack of access to traditional sources of capital like debt and equity add to the challenge. This year will see a few multi-state operators (MSOs) fold and sell off their component companies according to Lewis Goldberg, managing partner of  KCSA Strategic Communications“

Most of the MSOs have been run by financial operators Goldberg said, not operational experts, but “with the need to deliver results, that will change.”

Back To Basics

Businesses are focusing on the fundamentals to stay solvent or to make themselves attractive acquisition targets. Matt Hawkins, chief executive of Entourage Effect Capital a cannabis-only private-equity firm that has deployed more than $50 million into 32 companies says companies will â€œmake every effort to be more efficient.” They will still aggressively seek out new customer bases and explore innovation, he said, “but preserving margins will matter.”

Jeff Fallows, president of The Valens Company, says he also expects to see a marked improvement in the underlying fundamentals of the companies themselves. This will be a big year for the companies that execute well on their business plans, he said. Those companies will “emerge as leaders and those will be the ones to watch in 2020 and beyond. â€œ

Source: https://www.forbes.com/sites/forbestreptalks/2020/01/26/cannabis-industry-2020-predictions/#87768c3f31ff

Tags: , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – Cannabis Industry: 2020 Predictions $CGC $ACB $APH $CRON.ca $OGI.ca

Applied BioSciences $APPB: How CBD and The Endocannabinoid System Work Together $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 10:43 AM on Tuesday, January 21st, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

Before we can take a look at how CBD and the Endocannabinoid System (ECS) work together, we must first understand the ECS.

The human body has an endocannabinoid system, just like it has an endocrine system and a number of other systems that work together to function. The ECS is what makes it possible for CBD, THC, and other cannabinoids in the marijuana and hemp plants – there are hundreds – to work on the body.

In 1988, researchers found the first cannabinoid receptor in the brain of a rat. They found that the receptors interacted exclusively with receptors found in the cannabis compound, THC. That’s the cannabinoid everyone’s most familiar with because it is the compound responsible for the stoned feeling associated with marijuana consumption.

The researchers discovered that the receptors were concentrated in areas of the brain that plays a role in a number of physiological and mental processes, including emotion, motor coordination, high cognition, and memory.

In 1993, another cannabinoid receptor was discovered. It was found distributed throughout the immune system and peripheral body tissues. It displayed the same reaction to THC as the first receptor.

In 1995, the two receptors, that had been named CB1 and CB2, were found not only in rats, but in humans, and thousands of other species.

As technology advanced, researchers further explored the relationship between cannabinoid receptors in the body, known as endocannabinoids, and the cannabinoid receptors in cannabis compounds such as CBD oil and THC – known as phytocannabinoids.

What is the Purpose of Endocannabinoids?

The endocannabinoid system was discovered in the late 1990s, and since then, researchers have learned a great deal about the relationship between phytocannabinoids and endocannabinoids.

Because we know endocannabinoids are present throughout the body in numerous functions, researchers believe they may help maintain these functions.

Imagine for a moment the body is a machine, where each system works together to keep the machine moving and working. The immune system, for instance, would be the filtration system. The brain would be the motherboard, and the endocannabinoids help to maintain the systems.

CB1 receptors are concentrated in the brain and central nervous system. Your central nervous system is responsible for maintaining all the core functions such as pain perception, stress response, motor activity, and memory.

CB receptors are located in many of the peripheral organs in the body, suggesting they are core components of the cardiovascular system, the immune system, and the muscular system.

Why Phytocannabinoids Matter

Machines, whether due to natural aging, poor maintenance, or damage, may malfunction. And like those machines, our body’s systems and parts can break down and malfunction, causing issues within the entire body and any number of health conditions.

Endocannabinoids help maintains your body’s health, but if the level of endocannabinoids in the body declines, in theory, they’d only be able to maintain the body’s current state of health. As such, there likely wouldn’t be enough to stop it from declining any further. Over time, the health level decreases gradually, and in the process, creates bigger health problems.

That’s where phytocannabinoids, such as CBD come into play.

How CBD Works in the Body

Research has taught us that when CBD bonds with either the CB1 or CB2 receptors in the body, it either alters or improves that receptor’s capabilities, which improves that receptor’s functionality.

If the body is suffering a cannabinoid deficiency, adding them to your body, for example, by using CBD gummies for stress, helps to equalize the deficiency. Right now, studies point to the theory that cannabinoids are a finite resource. The deficiency of cannabinoids may cause a number of health issues, including irritability and headaches.

Essentially, using CBD enables us to boost our ECS. Because it bonds with our CB1 and CBD2 receptors, CBD helps the body maintain vital health functions and helps restore balance, also known as homeostasis, within the body. This is the reason it has so many health benefits.

CBD Benefits

When you really think about it, the majority of health problems can be traced back to an imbalance somewhere in the body.

In a healthy body, all is as it should be, and the body is balanced. In an unhealthy body, however, there is either too much or too little of something (or multiple somethings). This creates a disruption in homeostasis and presents a variety of symptoms, which vary depending on the nature of the imbalance.

Think about the various health conditions that are a result of imbalance, and how CBD can help improve these conditions by restoring balance:

  • Inflammation: This is often characterized by a part of your body swelling, and sometimes becoming hot. It can be incredibly painful, and range from mild, to severe enough to incapacitate someone. Inflammation in the body is linked to autoimmune disorders, arthritis, and bacterial infections. CBD can be helpful to treat inflammation because it suppresses the inflammatory pathways and responses, stimulates regulatory cell production, and manages our pain perception.
  • Seizures: Seizures are the result of erratic electrical impulses in the brain, which causes violent shaking in the body. In patients suffering from two severe forms of epilepsy known as Lennox Gaustat Syndrome and Dravet Syndrome, CBD reduces the number of seizures because it slows down the excitatory nerve activity and subdues the brain’s reaction to the intense signals that cause the overload.
  • Anxiety and stress: Most people experience stress and anxiety as a response to situations that are perceived as unwanted, dangerous, or risky. Hormonal imbalance or excessive messages in the brain boosts cortisol levels and causes you to feel stress. CBD combats this by regulating how your brain responds to stress signals and maintaining normal cortisol levels.

These, of course, are only a few examples of the studies supporting CBD as an effective treatment.

There are hundreds of other studies supporting its use to treat a wide number of other conditions, such as addiction, acne, depression, schizophrenia and more. It’s all because of our ECS, and the fact that our bodies contain parts linked directly to the cannabis plant is pretty amazing.

SOURCE: https://www.latintimes.com/how-cbd-and-endocannabinoid-system-work-together-454648

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB: How CBD and The Endocannabinoid System Work Together $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

NORTHBUD $NBUD.ca – Legalization 2.0 Product Rollout in Canada #Marijuana $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 12:59 PM on Monday, January 20th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Legalization 2.0 Product Rollout in Canada

  • The approval of these products is significant, both for consumers and for the cannabis industry in Canada
  • The infused products sector is large and very lucrative, and has already been hugely successful in parts of the US where cannabis is legal
  • It is also one with enormous growth potential. Some estimates suggest that the market will grow by a whopping $17 billion by 2022.

By Matt P

On October 17th, 2019, the Canadian government went ahead with the second phase of its cannabis program. Legalization 2.0 included the approval of edibles and infused products.  The move came exactly one year after the first wave of legalization which saw Canada make history, with recreational cannabis flower and oil hitting the legal market for the first time.

The approval of these products is significant, both for consumers and for the cannabis industry in Canada.  The infused products sector is large and very lucrative, and has already been hugely successful in parts of the US where cannabis is legal.  It is also one with enormous growth potential. Some estimates suggest that the market will grow by a whopping $17 billion by 2022.

While legalization occurred in October, Canadians still had not been able to purchase the new items. January 6th, 2020 marked the first day which vaporizers and cannabis-infused products were widely available to all Canadians.

Why Has It Taken So Long To Get Product Out?

Much of the delay has come from the restrictions imposed by the government.  All licensed producers looking to sell these new products are required to submit a 60 day notification directly to Health Canada. 

This means that the earliest date they would be available on shelves would be mid-December.  The timing was particularly important, since it fell right before the start of the holidays. Retailers and producers were looking to capitalize on making these hot new products readily available for holiday shoppers. 

Some retailers and consumers were lucky enough to get a limited supply before the holidays.  However, many had to wait until January 6th to finally get their hands on the new goodies.

Legalization 2.0 Product Rollout Across Canada

Whether or not you’ve had access to edibles before now depends largely on which part of Canada you’re living in. Consumers in British Columbia have had access to them since late December. Residents were able to purchase both through BC’s online store as well as through a number of private dispensaries. Edibles hit the shelves just in time for the holidays.  Saskatchewan was another province that saw edibles become available just before December 25th.

For other parts of the country, January 6th was the first time residents could pick up the new products.  In Ontario, Alberta and Quebec, the rollout for legalization 2.0 was delayed until January.  This was mainly due to the fact that all three provinces maintain their own distribution system, as opposed to allowing licensed producers to interact directly with retailers.

Image Courtesy of Alexander Stein

In Alberta, January 6th marked the first day that stores were able to place their orders with the AGLC, which acts as the cannabis wholesaler for the provinces retailers.  There are currently a limited number of products available, but that’s expected to change.  AGLC spokeswoman Heather Holman commented on the situation, saying that “right now in Alberta, AGLC has contracts with 43 federally licensed producers.  They manufacture a variety of products. About half of those licensed producers will be providing for what we’re calling cannabis 2.0 (which are) the new line of products like edibles, extracts and topicals. What we see this week and the coming weeks isn’t reflective of the bigger picture.”

In Ontario, online sales through the Ontario Cannabis Store began at 9:00am Thursday, January 16th. The store subsequently sold out of all product by 2:00pm on the same day.  The online retailer announced last week that they’d be carrying 59 new cannabis products.

Quebec and Legalization 2.0

The situation is significantly more complicated in the province of Quebec.  The province has the distinction of having the strictest cannabis laws in the country. The province also passed a law raising the age of consumption to 21 back in October.

Although they officially rolled out the new products this month, these strict laws extend to legalization 2.0.  In addition to heavy-handed age of consumption laws, the province has also passed a number of restrictions on these new products.  Infused products such as chocolates and baked goods have been banned.  So have vape pens and cartridges. Quebec officials enacted the bans based on fears that the products could appeal to minors.

For the time being, it seems that users in Quebec will have to make do with a much more limited selection than the rest of the country.

Issues And Potential Hurdles

Much like the original rollout of legal cannabis flower in 2018, things haven’t gone as smoothly as both the government and cannabis industry would have liked.  Along with the delays in multiple provinces, there have also been other issues.

The Aphria Recall

In a case of terrible timing, cannabis giant Aphria was forced to recall its line of vape pens. The recall was due to leaky vape cartridges.  According to chief corporate affairs officer Tamara Macgregor, “out of an abundance of caution we asked provincial customers to return certain initially shipped ‘510 cartridges’ that did not meet our intended consumer experience.”

Like most of the licensed producers in Canada, Aprhia has no doubt had their eyes set on this second wave of legalization (particularly given what a disappointing year 2019 was).

Vaping Restrictions

One of the big issues plaguing the cannabis industry over the past year has been the backlash against vaping across the country.  Effective as of January 1st, Ontario has implemented an advertising ban on all vape products in convenience stores and gas stations.  The move was prompted from data indicating that more young people are vaping, and is designed to bring the current laws in line with provincial tobacco laws.

Image Courtesy of Lexphumirat

The move didn’t effect the cannabis industry directly. The Ontario cannabis Store and licensed retailers are responsible for the sale of cannabis vapes. However, the fact that provincial lawmakers are willing to target vaping more broadly is troubling.  Along with Quebec, Newfoundland and Labrador have also banned cannabis vapes. Officials in British Columbia plan to raise taxes on these products specifically to 20%.

These moves have no doubt left the industry very concerned. Canada will continue to be a proving ground for legalization as Cannabis 2.0 rollout continues.

Source: https://www.puffpuffpost.com/legalization-2-0-rollout-canada-success-and-failure/

Tags: , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – Legalization 2.0 Product Rollout in Canada #Marijuana $CGC $ACB $APH $CRON.ca $OGI.ca

NORTHBUD $NBUD.ca – High demand: Ontario’s online #Cannabis 2.0 products sell out fast $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 2:56 PM on Thursday, January 16th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

High demand: Ontario’s online Cannabis 2.0 products sell out fast

By David George-Cosh

More than 2,000 people placed orders within the first hour that cannabis-infused edibles and vape products became available for sale on the Ontario Cannabis Store’s website, a spokesperson told BNN Bloomberg.

Beginning Thursday at 9 a.m. ET, the website listed 50 vape products and 21 pot-infused gummies for sale, a slight increase from the number of items available at Ontario’s brick-and-mortar cannabis retailers.

More than 3,000 people were waiting in a “digital queue” before the online sales began. Due to the high demand, the website experienced several crashes for some products, while all “soft-chew” items, or gummies, were sold out within the first 30 minutes.

OCS spokesperson Daffyd Roderick told BNN Bloomberg the government agency is managing the website’s traffic issues and plans to replenish any sold-out items after bricks-and-mortar stores have been allotted an equal share of available product.

“We know the licensed producers are working hard to make more products available and we’re confident that these growing pains will be moved through in relatively short order,” Roderick said.

While some of the next-generation cannabis products on the website have been available at physical Ontario cannabis stores since earlier this month, the various cannabis-infused cookies, soft chews, mints, tea and vapes for sale represent a potential new windfall for the country’s pot producers, who have been stymied over the past year with softer-than-expected revenue from dried flower products.

Raymond James analysts said in a recent report that cannabis producers should report material revenue from the latest rollout of Cannabis 2.0 products in the second-half of this year.

Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new — and controversial — Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Source: https://www.bnnbloomberg.ca/high-demand-ontario-s-online-cannabis-2-0-products-sell-out-fast-1.1375048

Tags: , , , , , , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – High demand: Ontario’s online #Cannabis 2.0 products sell out fast $CGC $ACB $APH $CRON.ca $OGI.ca

Applied BioSciences $APPB: CBD vs THC – Full Spectrum, Broad Spectrum and Pure Isolate 2020 Comparison Guide $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:34 PM on Tuesday, January 14th, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

A properly updated 2020 guide on CBD versus THC along with a complete review of the entourage effect differences and health benefits of using a full spectrum, broad spectrum or pure isolate CBD-infused product.

HealthMJ is actively mapping out the entire CBD ecosystem, from the best CBD oils, gummies, skincare, salves/balms, drinks/beverages and pet products – we got you covered; and one of the most popular questions we receive from our attentive audience is how CBD vs THC works; more specifically the differences between full spectrum CBD, broad spectrum CBD and pure isolates.

As the rapidly shifting landscape of medicinal cannabis continues to unfold in 2020, hemp and marijuana plants are both spectacles to watch in their own right given the prominent cannabinoid community of compounds, namely in THC and its cousin phytocannabinoid CBD.

With all of the new information coming out about CBD and its potential health benefits, it’s only fair that you might question how CBD compares to marijuana or THC-infused products and so forth. Many individuals continue to be concerned about CBD, and while there are many risks and dangerous concerns to address, research says maybe you should consider the options to get ahead of the curve and know the variations best available for you.

When it comes to terms like CBD, THC, full-spectrum, broad-spectrum, and isolates; it’s hard to know and fully understand what these terms mean and just what the differences are between them or how they compare to one another. But our CBD vs THC guide is designed to do just that; remove the clutter, simplify the terminology and showcase each advantage they all have independently as well as talk about the ‘entourage effect’.

The thing is, there is a lot of varying CBD and THC-infused product information available, and it is so very important to educate yourself before passing any judgment on these products. Making an effort to be in the know will not only increase your knowledge base but just might present you with life-changing information given your occupation, bodily needs or desired medicinal effects.

Understanding that “knowledge is power,” we put together a guide the will detail each of these items in turn (CBD, THC, full-spectrum, broad-spectrum, and isolates) as well as compare them and explain to you how each of these factors might relate to the other.

We will share with you various statistics, studies, definitions, and a ton of valuable information for each subject. To begin, we will break down each subject separately, and then we will come back and tie some information together for your reference.

We hope you will tune into this CBD and THC overview breakdown and the valuable information presented within our cannabis oil-infused product guide for buying the best full-spectrum, broad-spectrum or pure isolate option for you.

CBD: All the Rage, None of the High

CBD products have taken the world by storm. While it has quickly become the most popular best-selling herbal extract in the health and wellness industry last year, many are still on the fence whether or not to use a CBD-infused supplement. Have you tried them yet? Are you scared to take that step and open the door to the possibilities of what CBD can provide for you? CBD products were initially quite controversial as they are instantly associated with marijuana.

The truth is, CBD really is not comparable to marijuana and, in fact, many times contains no THC (which is the property that typically enacts psychoactive responses in use of marijuana) or a minuscule percentage.

Additionally, CBD products are heavily regulated as to how much THC can legally be in them for over-the-counter distribution. It is no secret by now CBD has become a go-to option for many men and women looking for a natural and potentially reliable solution for issues such as pain relief, anxiety, irritation, and the like. Before choosing a CBD product, it is important to understand the difference between the three of the most common-types of formulas, which are full-spectrum (with THC), broad-spectrum (no-THC) and isolate (pure CBD). Fortunately, this post is here to help.

Are you curious yet? Let’s dive a bit deeper.

What Exactly is CBD?

CBD is short for cannabidiol. This cannabidiol is otherwise known as a phytocannabinoid. These cannabinoids come directly from the cannabis plant. Cannabis plants contain more than 100 cannabinoids in them.

When minerals are extracted from the cannabis plant, CBD accounts for approximately 40% of the extracts, which results in CBD being readily available for processing. CBD can be obtained from hemp without THC in the extraction.

What does that mean? THC is the property that often gives cannabis a bad name. It is THC that produces the “high” that is associated with some cannabis usage, particularly smoking cannabis. However, you should know that THC is either extremely limited or completely non-existent in CBD when it is produced.

In fact, many manufacturers of CBD products extract the cannabidiol with an extreme process specifically for the purpose of delivering a pure product and reducing THC levels. In this manner, the CBD then does not make you high and formats to legal regulations as well.

The Benefits of CBD

Studies have shown that CBD products can produce a significant number of health benefits, many of which you may not have ever been aware of. Research has been increasing, but there is also still a lot to learn about CBD.

There are many benefits that have been discovered through studies and trials thus far. Here are a few of the most common and well-known benefits of CBD products:

  • Pain Relief
  • Anti-inflammatory properties
  • Anxiety relief
  • Cancer treatment and relief
  • Epilepsy and seizure disorder treatments
  • Alzheimer’s treatment
  • Migraine relief
  • Fight acne
  • Fights neurological symptoms and disorders

You might be able to pick out a few of the items on this list that have been primarily untreatable with everyday medication. When there is medication available, it can have extensive side effects.

But consider a safe and legal treatment to things like cancer, epilepsy, and Alzheimer’s – amongst other hard to treat diagnoses. Does this mean CBD will help your body heal from these disorders, or will it simply help relieve the symptoms?

Research and studies are still new and not fully conclusive. It is hard to say whether CBD could essentially eliminate any of the disorders listed, but if it can help fight or treat the associated symptoms, it is certainly worth consideration.

To give you an idea of how CBD works with these various disorders, let’s break a few of them down further.

CBD and Alzheimer’s Treatment

Alzheimer’s has long been a disorder that is primarily untreatable. Of course, there is medication to help those with Alzheimer’s, but it does little by way of reducing symptoms or slowing the process of the disease.

Alzheimer’s is primarily a brain disorder that progresses rather slowly at most times. It can move quickly though in some people. Alzheimer’s causes the victim to lost memories, history, and even the memory of how to complete specific skills necessary to care for themselves.

As Alzheimer’s progresses, many people revert to old memories and don’t know the people closest to them when they see them. They forgot how to do basic tasks and ultimately become unable to care for themselves safely.

All of these effects of Alzheimer’s are functionally related to the brain suffering from inflammation. This inflammation often causes excessive oxygen to build-up, which in turn leads to the effects we are familiar with as Alzheimer’s. The brain cells become blocked and therefore decline.

In comes CBD products, recent studies show that CBD can reduce this inflammation, allowing that oxygen that has built up due to brain cell blockage to seep out and therefore decreasing many Alzheimer’s symptoms.

This systematic process from CBD acts as an antioxidant for the brain cells by reducing or eliminating the inflammation that causes blockage and therefore causes the disease to take full form. With this relief, the effects of Alzheimer’s are greatly reduced and slowed.

This is not to say CBD cures Alzheimer’s but rather that it can reduce the process and provide relief of many of the symptoms, straight from the root cause.

CBD and Epilepsy Treatment

Epilepsy and other seizure disorders have been studied for health benefits related to CBD treatment. Epilepsy is another neurological disorder in which the sensory processes in your brain are triggered, which then leads to seizures.

Epilepsy has been challenging to treat through the years and at times, is left untreated. There are medications available, but there is no guarantee they will work. They may reduce seizures or the intensity of seizures, but the results vary on individuals, and, of course, the results are only as good as the medicine available.

CBD, also, may not be effective for every user. However, it has been found in studies to dramatically reduce the number of seizures as well as the length of seizures in those affected by the disease.

In 2018, the FDA approved Epidiolex to be used for epilepsy treatment in certain situations. There are two forms of epilepsy it has been approved to treat and an age requirement as well. Epidiolex is a formula of CBD that is purely plant-based but has been studied and researched for its effectiveness in regards to epilepsy treatment.

CBD Pain & Anti-Inflammatory Relief

For a number of years, chronic pain has been treated with pain relievers. Pain relievers that can cause dependency and addiction for the user and often produce side effects that far outweigh the relief of the pain.

Not only can pain relievers lead to addiction but essentially, they can become ineffective because of the dependence effect they tend to have on the user. This is an unfortunate effect for those who are simply seeking relief.

We’ve grouped Pain relief and anti-inflammatory properties together here because they are often related. Chronic pain is typically directly related to inflammation, as are various diseases and disorders that lead to common pain, fibromyalgia, sclerosis, lupus, etc.

Research is still quite limited on CBD’s abilities to reduce pain or inflammation, and therefore, there is no FDA seal of approval yet, but that doesn’t mean there isn’t information available for review.

It is believed through current studies that CBD directly communicates to your ECS or endocannabinoid system. This system signals cells to emit pain signals to your body when an area is damaged. CBD interacts with ECS to improve the quality of these signals, relieving the feelings of pain or inflammation within your body.

CBD and Anxiety Relief

Anxiety has become one of the fastest rising disorders. Anxiety continues to become a common diagnosis, but it shouldn’t be. In this frantic world that is constantly changing and evolving, anxiety is the last thing we should be worried about, and clearly, it is all about “worry.”

Again, research is just beginning, and the results are currently limited. The results of these studies continue to be tested, but for now, we work with what limited information we have available. Studies are showing that CBD can dramatically reduce anxiety and the effects of anxiety.

How does that work? CBD enhances calming properties through the brain. CBD somehow is able to bind to those brain receptors that trigger the anxiety response from your brain, and therefore, your anxiety is reduced, and you remain calmer and more reasonable rather than anxious and concerned.

Do You See a Connection?

Many of the disorders and symptoms you see above have something in common, they are triggered by cells or brain receptors that essentially lead to the disease or disorder. CBD appears to work quite well with disorders that essentially start with brain function.

Studies are still limited and are still taking place. Results are varied, and there is not yet enough evidence to truly rely on CBD, but there are positive results and signs thus far. While many of the disorders we specifically discussed are brain-related, CBD can have positive effects on other ailments as well.

The Legalities of CBD

CBD-infused product supplementation was the number one most trending ingredient in 2019. They have become more pronounced and popular in recent years as people discover just what CBD can offer for health benefits. There are a number of benefits and things still being discovered about CBD and what it has to offer.

It seems like everywhere you go, you can find CBD products from oils, gummies, sprays, and lotions to even CBD pet products. But is it really legal? How do you know it won’t cause you legal issues in the end?

Cannabis is certainly not new, but it still has limited legality for sales, use, and distribution. It cannot be openly sold in many states. Only a few states have passed bills allowing recreational or medicinal use of marijuana in a legal capacity.

However, in 2018, the Farm Bill was passed/updated, and restrictions on CBD specifically were removed from various legal restrictions if the CBD is extracted from a hemp plant. It is now legal to produce, buy, and sell CBD products IF they contain less than .3% THC.

The primary statement here is the products must fall into the guidelines of following the THC level guidelines. Many CBD companies simply meet the minimum guidelines while others take it even farther and purify their CBD or even produce a formula with 0% THC.

SOURCE: https://www.healthmj.com/cbd/thc-full-spectrum-broad-spectrum-isolate/

Tags: , , , , , , , , , ,
Posted in All Recent Posts | Comments Off on Applied BioSciences $APPB: CBD vs THC – Full Spectrum, Broad Spectrum and Pure Isolate 2020 Comparison Guide $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Spyder #Cannabis $SPDR.ca – DOPE! New cannabis compound 30 TIMES more potent than #THC found in one #marijuana variety $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 1:00 PM on Monday, January 13th, 2020

SPONSOR: Spyder Cannabis (SPDR:TSXV) An established chain of high-end vape stores. Aggressive expansion plan is already in place that will focus on Canadian retail and US Hemp derived kiosks in high traffic areas. Click here for more info.

DOPE! New cannabis compound 30 TIMES more potent than THC found in one marijuana variety

  • Compound is one of two newfound cannabinoids that have been discovered in the Cannabis plant glands of the sativa L species.

By: Charlotte Edwards

A NEW cannabis compound has been discovered and it may be 30 times more potent than THC.

Scientists aren’t yet sure whether the compound causes a high or has medical benefits so they’ve been conducting tests to try and figure this out.

The compound is one of two newfound cannabinoids that have been discovered in the Cannabis plant glands of the sativa L species.

Cannabinoids is the collective term for the group of diverse chemical compounds that act on the cannabinoid receptors of the brain.

THC is just one of these cannabinoids and it’s currently considered to be the principal psychoactive component of cannabis.

THC, or tetrahydrocannabinol, plugs into brain receptors and can alter our ability to co-ordinate movements, reason, record memories and perceive things like time and pleasure.

  THC in cannabis is what can give smokers a high feelingCredit: Getty – Contributor

It’s thought that cannabis contains over 140 similar chemicals that can interact with receptors all over the body.

However, THC is currently the only one we know can result in a high spaced out feeling.

Of the two new cannabinoids discovered, one looks similar to the compound CBD, which isn’t psychoactive.

The other appears similar to THC but may even produce stronger mind-bending effects.

This THC lookalike is called tetrahydrocannabiphorol (THCP).

Recent research suggests that it interacts with the same brain receptor as THC but has slight differences in its chain of atoms.

The slight difference in shape of THCP means it can technically fit more snugly into its preferred brain receptor than THC.

A test showed that the compound can actually bind 30 times more reliably than THC.

When given to lab mice, the THCP made them behave as if they were on THC with slower movements and decreased reactions to pain.

The mice reached this state with a much lower does than would have been required with THC meaning the new compound is stronger.

However, this lab experiment still doesn’t mean that the same effect would happen in humans.

THCP doesn’t appear to be present in large amounts in cannabis plants but even if it was, increased psychoactive properties would still not be guaranteed.

Source: https://www.thesun.co.uk/tech/10725348/new-cannabis-compound-more-potent-weed/

Tags: , , , , , , , ,
Posted in All Recent Posts, Spyder Cannabis Inc. | Comments Off on Spyder #Cannabis $SPDR.ca – DOPE! New cannabis compound 30 TIMES more potent than #THC found in one #marijuana variety $CGC $ACB $APH $CRON.ca $OGI.ca

PRIMO Nutraceuticals Inc. $PRMO.ca – 2020 could be a defining year for the #cannabis industry #CBD $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 9:00 PM on Sunday, January 12th, 2020

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

2020 could be a defining year for the cannabis industry

  • “There’s going to be a lot of movement in 2020,” said Chris Walsh, chief executive officer of Marijuana Business Daily, a cannabis industry trade publication. “Whether it leads to actual legalization in some states remains to be seen.”

By Alicia Wallace, CNN Business

New York (CNN Business)2019 was a momentous year for the cannabis industry: Hemp-derived CBD had a heyday, Illinois made history, California got sticky, vapes were flung into flux, and North American cannabis companies received some harsh wake-up calls. 2020 is gearing up to be an even more critical year.   There’s a well-worn saying in the cannabis business that the emerging industry is so fast-moving that it lives in dog years. 2020 is barely a week old, and cannabis is already making headlines after Illinois kicked off the new year with recreational sales. Other states are inching closer to legalization this year — with several mulling how best to ensure social equity. Also in 2020, there’s the FDA could chill the CBD craze, and a move from Congress could change the game entirely. The tumultuous past few months have set 2020 up to be a make-or-break year for some of the biggest in the business as well as the scores of lesser-known players priming to make their moves.   “There’s going to be a lot of movement in 2020,” said Chris Walsh, chief executive officer of Marijuana Business Daily, a cannabis industry trade publication. “Whether it leads to actual legalization in some states remains to be seen.”

The next US states to legalize cannabis

Fourteen US states and territories have legalized recreational cannabis sales for adults (although regulations aren’t fully fleshed out in places like the District of Columbia and Vermont). A total of 33 states have legalized cannabis for medical purposes. Illinois will remain in focus, after it made history last year with the first legislatively-enacted recreational cannabis program. Critical aspects of its program include social equity and social justice measures created to help people and communities most harmed by the War on Drugs.   “Underserved groups are holding the industry accountable,” said Gia Morón, executive vice president for Women Grow, a company founded to further the presence of women in the cannabis industry. “And our legislators are recognizing that [social, gender and minority concerns] are a part of this now.”   New York and New Jersey have been flirting with legalization but have held off to navigate some logistics related to aspects that include social equity. The governors of New York, New Jersey, Connecticut and Pennsylvania convened this past fall for a summit on coordinating cannabis and vaping policies. New Jersey is putting a recreational cannabis measure before voters in November, and Gov. Andrew Cuomo vowed Wednesday that New York would legalize cannabis this year. Other possibilities for states to legalize recreational cannabis could be Arizona, Delaware, Florida, Minnesota, Montana, New Mexico, North Dakota and South Dakota, Walsh said. Even Alabama, Mississippi and South Dakota could become new medical cannabis markets and other states’ medical programs could see expansions, he added.   “If you look at the map right now of the US, we’re getting to the point where there isn’t that many [states] left that can legalize,” he said. “You can look at any of those and say there might be a chance in the next year or two for them to legalize.”

Federal legalization

Whether national legalization is on the horizon remains to be seen, said Walsh. How federal agencies regulate hemp, a cannabis plant with under 0.3% tetrahydrocannabinol (THC), and derivatives such as cannabidiol (CBD) could be extremely telling for how the US government might approach regulation of other forms of cannabis down the road, he said. CBD products have been all the rage, but they may be on shaky ground. CBD oils, creams, foods and beverages have seen an explosion in availability following the passage of the 2018 Farm Bill, which legalized hemp but left plenty of discretion to the US Food and Drug Administration, which regulates pharmaceutical drugs, most food items, additives and dietary supplements. The FDA is reviewing CBD and has yet to issue formal guidance, although the agency has issued warning letters to CBD makers that make unsubstantiated health claims. Class action lawsuits have been filed against several CBD companies, including two of the largest, Charlotte’s Web and CV Sciences, alleging they engaged in misleading or deceptive marketing practices, Stat News reported.   Cannabis insiders are closely awaiting the fate of industry-friendly bills such as the STATES Act, which would recognize cannabis programs at the state level, and the SAFE Banking Act, which would allow for banks to more easily serve cannabis companies. Those and other bills likely won’t pass in full, but it’s possible that some language makes it into more comprehensive legislation, Walsh said.   “It feels like [legalization] has to happen soon, but it might not happen how people think. You get a bill passed to allow banks to clearly serve this industry without a whole bunch of restrictions, and that could be pseudo-legalization,” Walsh said. “So, the actual move by the federal government to ‘legalize’ marijuana or let states decide might not come for years; but that reality might play out anyway with some other type of legislation.”

New regulation in older markets

In addition to the promise of new markets, the evolution of established cannabis programs could also play a significant role in the cannabis business landscape. In California, the world’s largest cannabis industry has developed in fits and starts. Regulators are taking aim at an entrenched illicit market as businesses decry tax increases and local control measures that limit distribution.   “California is going to get worse before it gets better,” Walsh said. And in Colorado, where the nation’s first legal recreational cannabis sale took place, a slate of new laws are poised to shift the cannabis landscape by allowing for social consumption businesses and the ability for out-of-state and publicly traded companies to own licenses.

New products come to Canada

Canada’s “Cannabis 2.0” roll-out of derivative products — such as edibles, vapes and beverages — is in its beginning stages. The Canadian publicly traded licensed producers that have been beset by missed and slow market development have bet heavily on these new product forms.     But it takes time for provincial and state cannabis programs to get off the ground, for businesses to come online and for production and supply to get in a good balance with demand. So any big returns won’t happen immediately, said Morgan Paxhia, managing director and co-founder of cannabis investment firm Poseidon Asset Management. “It’s not going to look any better in Q1 and really into Q2,” he said of the Canadian cannabis sector.

‘Blockbuster failures’

Overall, 2020 should bring volatility for cannabis companies in Canada and the United States, he said, noting the industry’s current business cycle is mirroring that of the dot-com bubble and subsequent burst.   “There were very good companies that have emerged from that period, but most of the companies during that time are gone,” he said. Paxhia expects at least one — if not several — “blockbuster failures.”   The capital constraints are expected to continue into the first leg of 2020 as some initial bets don’t pan out for some companies, said Andrew Freedman, Colorado’s former cannabis czar who now runs Freedman & Koski, a firm that consults with municipalities and states navigating legalization. Some companies’ low points could create opportunities for other firms and investors that waited out the first cycle, Freedman said.   “In 2020, I see that everybody will understand the economics of cannabis a little bit better,” he said.   Source: https://edition.cnn.com/2020/01/09/business/cannabis-2020-legalization/index.html

Tags: , , , , , ,
Posted in All Recent Posts | Comments Off on PRIMO Nutraceuticals Inc. $PRMO.ca – 2020 could be a defining year for the #cannabis industry #CBD $CROP.ca $VP.ca NF.ca $MCOA

Spyder #Cannabis $SPDR.ca – Exploring Canada’s Cannabis Demand-Supply Landscape $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:48 PM on Thursday, January 9th, 2020

SPONSOR: Spyder Cannabis (SPDR:TSXV) An established chain of high-end vape stores. Aggressive expansion plan is already in place that will focus on Canadian retail and US Hemp derived kiosks in high traffic areas. Click here for more info.

Exploring Canada’s Cannabis Demand-Supply Landscape

By Sushree Mohanty

  • Cannabis demand is rising
  • However, there seems to be a gap between cannabis demand and supply in Canada
  • It’s been a year since Canada legalized marijuana, but it seems consumers in the country are still struggling to obtain legal cannabis
  • This demand-supply imbalance took a toll on cannabis companies’ revenues and stock prices last year

Let’s take a closer look at the demand-supply imbalance in Canada.

The cannabis demand-supply landscape in Canada

Health Canada has come up with a national Cannabis Tracking System to keep track of the cannabis produced and sold across the country. The intention is to keep a check on illegal cannabis sales. Health Canada requires federal license holders and provincial and territorial growers to report this data on a monthly basis.

Another objective behind this move could be to ensure that cannabis producers aren’t growing marijuana illegally. Such was the case last year with CannTrust (NYSE:CTST). The company was found to be growing marijuana illegally and was reportedly in violation of Health Canada’s regulations.

The monthly report tracks the sales of medical and recreational marijuana. It also takes into account the cannabis inventories held by retailers and distributors. Here are a few details from the report for the period that ended on September 30, 2019:

  • Total sales of dried cannabis fell by 0.4% to 12,922 kilograms on a month-to-month basis.
  • Cannabis oil total sales rose by 4.8% to 11,187 liters on a month-to-month basis.
  • The total amount of finished dried cannabis inventory rose by 5% to 64,151 kilograms on a month-to-month basis.
  • The total amount of finished cannabis oil inventory rose by 1.1% to 102,060 liters on a month-to-month basis.

“Finished inventory” here implies that the products are ready and packed for sale. The finished inventory for dried cannabis was higher for both provincial and territorial distributors and retailers and federal license holders.

For dried cannabis, federal license holders saw a 5.7% increase in finished inventories, while provincial and territorial distributors and retailers saw a 4.3% increase. Additionally, for cannabis oil, federal license holders saw a 2.6% increase in inventories, while provincial and territorial distributors and retailers saw a 1.4% decrease.

What caused the imbalance?

Canada legalized marijuana in October 2018. The demand for marijuana was high in the country. Thus, producers cultivated more cannabis, hoping to meet this demand. However, regulatory procedures were slow and strenuous, which resulted in a delay in the licensing and opening of new legal stores. The delay resulted in higher inventories and caused supply issues. Hence, cannabis sales were affected across Canada. Looking at the data for September, we can conclude that most retailers had products ready for sale. However, the lack of stores caused a supply issue and a rise in inventory.

Moreover, the licensing process isn’t that simple. A Cannabiz Media article stated, “The amount of time to obtain a license to grow marijuana in Canada’s legal market was excessive with some cultivators waiting months or even a year. Once a grower obtained a cultivation license, it needed to produce two full crops, have them tested, get its sales software audited, and apply for a sales license, which could take another year.”

How’s the marijuana demand and supply situation in the US?

While we’re on the subject, let’s talk about the demand and supply situation in the US. Marijuana isn’t legal at the federal level in the US. However, 33 states and the District of Columbia allow medical marijuana. Additionally, 11 states and the District of Columbia allow recreational marijuana.

Black market sales are a matter of concern even in the US. California, which legalized medical marijuana in 1996 and adult-use marijuana in 2016, also suffers from illicit cannabis activity. An article by Cannabis Business Plan discussed how cannabis consumers in the state will initially be inclined toward the illegal market to avoid regulatory costs. The article also stated that predictions show that by 2022, the marijuana market in the state could be worth $7.7 billion driven mostly by recreational marijuana.

Cannabiz Media also discussed how states such as Michigan are facing supply shortages due to a lack of licensed growers. Recently, recreational marijuana sales went live in Michigan. Pennsylvania faced similar problems when demand for medical cannabis couldn’t match supply in the state.

Furthermore, the abundance of marijuana resulted in losses for many licensed cultivators as prices fell. Obtaining capital for cannabis businesses is still an issue in the US. Banks and financial institutions are scared to provide help to cannabis companies because marijuana is still illegal federally. However, hopes are that the passing of the SAFE Act could smooth this process.

How are cannabis companies coping with the demand-supply situation?

The demand-supply imbalance hit cannabis companies’ revenues and profitabilities last year. After Canada legalized cannabis, companies increased their production capacities to match demand. However, the lack of legal stores caused a supply issue. Initially, Ontario was strict with its cannabis laws. Recently, though, after the second phase of legalization, Ontario relaxed its laws to tackle the problem of black market sales. Canada’s three largest provinces now expect higher sales this year from the Cannabis 2.0 expansion.

Hence, Aurora Cannabis (NYSE:ACB), Canopy Growth (TSE:WEED), Cronos Group (NASDAQ:CRON), and HEXO (TSE:HEXO) have struggled with overproduction. The companies missed their revenue targets and reported lower profitabilities in 2019. HEXO even withdrew its fiscal 2020 outlook due to lower store rollout issues.

Cannabis edibles are in high demand among marijuana products. Hence, consumers turned to the black market to obtain these products when Canada hadn’t legalized edibles. The prices of cannabis products on the black market are also lower than they are on the legal market. Now, with Cannabis 2.0 products ready to hit the stores, marijuana companies expect to recover their losses in 2020. These companies are ready with a variety of edibles, vapes, and beverages.

Though analysts expect a turnaround in 2020, they’ve kept a subdued outlook on marijuana companies’ 2020 revenues. Some analysts feel regulations and licensing delays could still affect Cannabis 2.0 revenues this year. Companies’ 2020 revenue estimates are as follows:

  • Aurora Cannabis’s fiscal 2020 revenue could be around 371.6 million Canadian dollars.
  • Canopy Growth’s (NYSE:CGC) fiscal 2020 revenue could be around 403.3 million Canadian dollars.
  • Cronos Group’s fiscal 2020 revenue could be around 146.1 million Canadian dollars.
  • HEXO’s fiscal 2020 revenue could be around 79.1 million Canadian dollars.

Final thoughts

The demand-supply imbalance in the cannabis market is an important issue. However, we also have to consider that the industry is a growing one and will have its ups and downs. Currently, the flow of regulations isn’t smooth, which is causing licensing and cultivation delays. It may take some time for things to smooth out in the industry.

Many also feel that federal legalization will help balance the demand-supply issue in the US. Nevertheless, considering the efforts by Canada and certain states in the US, we can expect a turnaround in 2020.

Stay tuned to learn more about the ins and outs of the marijuana industry.

Source: https://articles2.marketrealist.com/2020/01/exploring-canadas-cannabis-demand-supply-landscape/#

Tags: , , , , , , , ,
Posted in All Recent Posts, Spyder Cannabis Inc. | Comments Off on Spyder #Cannabis $SPDR.ca – Exploring Canada’s Cannabis Demand-Supply Landscape $CGC $ACB $APH $CRON.ca $OGI.ca

North Bud Farms $NBUD.ca Provides Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:16 PM on Thursday, January 9th, 2020
  • In late December completed first harvest at Salinas, California cultivation facility
  • Harvested 2,687 plants that were included in the acquisition of the Qlora Group

TORONTO, Jan. 09, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to provide shareholders with the following corporate update:

Cannabis Production Facility in Salinas, California

In late December we completed our first harvest at our Salinas, California cultivation facility. We harvested 2,687 plants that were included in the acquisition of the Qlora Group (“Qlora”). The Company anticipates completing testing and sale of the product in late January 2020, which will represent the first revenue generated by the Company in California.  The Company has also completed an in-depth review and analysis of both the infrastructure and cultivation practices and will be implementing significant efficiencies over the course of the next four harvests. The Company anticipates continual harvests of 2,000-3,000 plants every 25 days, with quality and yield improving with each harvest. This product will be sold via wholesale agreements to existing Qlora clients in the interim as we prepare for the launch of NORTHBUD branded flower products in California in the third quarter of 2020.  

“Despite challenges faced by the cultivation team during this period of transition, we are extremely excited to be harvesting our first crops and look forward to continual improvements as we implement procedural and infrastructure efficiencies,” said Justin Braune, President of Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD.

Cannabis Production Facility in Reno, Nevada

The Company is pleased to announce the completion of the first harvest of approximately 175 indoor grown plants. Upon the completion of testing and processing, the product will be distributed as NORTHBUD flower, pre-rolls and infused pre-rolls into selected Nevada dispensaries. The launching of NORTHBUD branded products into Nevada marks a significant milestone for the Company.

Status of Cultivation Licence Application for Cannabis Production Facility in Low, Quebec

On September 18, 2019, the Company received a confirmation of receipt of the site evidence package submitted in late August 2019. On November 22, 2019, the Company received a request for information from Health Canada (the “Request”).  The Request was received within the 60-business day service window for feedback provided by the regulator.  The Company is pleased to report that the Request was responded to in full in advance of the December 8th deadline. The Request did not contain any notices of deficiencies in the Company’s cultivation licence application nor did it require the Company to make any modifications or changes to its facility.

On December 19, 2019 the Company received a subsequent follow-up request for information consisting of two questions which were responded to that same day, and on December 20th, the Company received a request to clarify the roles of recently-hired employees in relation to the requested cultivation licence. This request was responded to in full on January 3, 2020. The Company has received no further communication from Health Canada.

The Company is confident that the approval process is on track and within comparable timelines experienced by other publicly-traded companies who have recently submitted evidence packages.  At this time, the Company cannot predict when it will be granted a cultivation licence by Health Canada. The Company will update shareholders on any further progress on the application.

Annual General Meeting

The Company wishes to inform shareholders that it will hold its Annual General and Special Meeting at 1:00 p.m. ET on Monday, February 3, 2020 at the office of McMillan LLP, World Exchange Plaza, Suite 2000, Ottawa, Ontario. The Company will file the required information for the annual and special meeting under its issuer profile on SEDAR at www.sedar.com.

Staffing and Personnel

The Company is pleased to announce the hiring of Adam Shapero as General Counsel. Adam comes to NORTHBUD after serving as Director of Risk Management, Corporate Secretary and Senior Counsel at Origin House (CSE: OH), who was recently acquired by Cresco Labs (CSE: CL) in a transaction valued at ~ $520 million. “We are extremely pleased to welcome Adam to our team,” said Sean Homuth, CEO of NORTHBUD. “His first-hand experience in the Cannabis industry will add tremendous value to our team while reducing our reliance on external counsel.”

About North Bud Farms Inc.

North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a license under The Cannabis Act.  The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has acquired cannabis production facilities in California and Nevada. The Salinas, California property is located on 11 acres which currently consists of a 300,000 sq. ft. of licensable greenhouse space with 60,000 sq. ft. actively cultivating cannabis and a 2,000 sq. ft. building licensed for distribution.  The Reno, Nevada property is located on 3.2 acres of land which was acquired through the acquisition of Nevada Botanical Science, Inc. a world class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation which holds medical and adult use licenses for cultivation, extraction and distribution.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, including, but not limited to, those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management.

Forward-looking statements, including, but not limited to, those regarding the success of the Company’s licence application in Quebec, future sales of cannabis in California and Nevada, plant harvest yields at the Company’s California and Nevada operations, conditions in the cannabis market, the Company entering agreements in connection with the B2B supply of cannabis and the Company’s transition into a revenue generating operational phase of development are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Provides Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

« Older Entries
Newer Entries »